Apotex: Observation Of Efficacy Endpoints Not Given Patentable Weight
ALEXANDRIA, Va. — In a Sept. 9 petition for inter partes review of a Regeneron Pharmaceuticals Inc. patent directed to a treatment for age-related macular degeneration (AMD), Apotex Inc. asserts that...To view the full article, register now.
Already a subscriber? Click here to view full article